{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:28:31Z","timestamp":1789720111170,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vaccine.2023.08.051","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:07:16Z","timestamp":1693667236000},"page":"6261-6271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["GMP manufacture of Shigella flexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers"],"prefix":"10.1016","volume":"41","author":[{"given":"Christopher","family":"Duplessis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9562","authenticated-orcid":false,"given":"Kristen A.","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ross Turbyfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-280X","authenticated-orcid":false,"given":"Ashley N.","family":"Alcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-7880","authenticated-orcid":false,"given":"Mark S.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tida","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey P.","family":"Weerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Lynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin V.","family":"Oaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7258-1690","authenticated-orcid":false,"given":"Chad K.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-5694","authenticated-orcid":false,"given":"Robert","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9859","key":"10.1016\/j.vaccine.2023.08.051_b0005","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2023.08.051_b0010","first-page":"e321","article-title":"Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis. Lancet Glob","volume":"7","author":"Anderson JDt, Bagamian KH, Muhib F, Amaya MP, Laytner LA, Wierzba T,","year":"2019","journal-title":"Health"},{"key":"10.1016\/j.vaccine.2023.08.051_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990\u20132016","author":"Khalil","year":"2018","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.vaccine.2023.08.051_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-018-0077-1","article-title":"Travelers' diarrhea: update on the incidence, etiology and risk in military and similar populations - 1990\u20132005 versus 2005\u20132015, does a decade make a difference?","volume":"5","author":"Olson","year":"2019","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"10.1016\/j.vaccine.2023.08.051_b0025","article-title":"Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus","volume":"13 Suppl 3(Suppl 3):S11","author":"Das","year":"2013","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2023.08.051_b0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3329\/jhpn.v31i3.16515","article-title":"Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis","volume":"31","author":"Ajene","year":"2013","journal-title":"Journal of Health, Population, and Nutrition"},{"issue":"5","key":"10.1016\/j.vaccine.2023.08.051_b0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/jtm.12049","article-title":"Post-infectious sequelae of travelers' diarrhea","volume":"20","author":"Connor","year":"2013","journal-title":"Journal of Travel Medicine"},{"key":"10.1016\/j.vaccine.2023.08.051_b0040","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-230X-13-46","article-title":"Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness","volume":"13","author":"Porter","year":"2013","journal-title":"BMC Gastroenterology"},{"issue":"5","key":"10.1016\/j.vaccine.2023.08.051_b0045","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3899\/jrheum.121254","article-title":"Pathogen-specific risk of reactive arthritis from bacterial causes of foodborne illness","volume":"40","author":"Porter","year":"2013","journal-title":"The Journal of Rheumatology"},{"issue":"4","key":"10.1016\/j.vaccine.2023.08.051_b0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7205\/MILMED-D-12-00510","article-title":"Quantifying the Incidence and Burden of Postinfectious Enteric Sequelae","volume":"178","author":"Porter","year":"2013","journal-title":"Military Medicine"},{"issue":"9888","key":"10.1016\/j.vaccine.2023.08.051_b0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2023.08.051_b0060","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/S2214-109X(15)00151-5","article-title":"Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED)","volume":"3","author":"Platts-Mills","year":"2015","journal-title":"The Lancet Global Health"},{"issue":"13","key":"10.1016\/j.vaccine.2023.08.051_b0065","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1017\/S0950268814003446","article-title":"Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012","volume":"143","author":"Gu","year":"2015","journal-title":"Epidemiology and Infection"},{"issue":"19","key":"10.1016\/j.vaccine.2023.08.051_b0070","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMra1207777","article-title":"Enteropathogens and chronic illness in returning travelers","volume":"368","author":"Ross","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2023.08.051_b0075","doi-asserted-by":"crossref","unstructured":"O'Ryan M, Vidal R, del Canto F, Carlos Salazar J, Montero D. Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. Human vaccines & immunotherapeutics. 2015;11(3):601-19.","DOI":"10.1080\/21645515.2015.1011578"},{"issue":"8","key":"10.1016\/j.vaccine.2023.08.051_b0080","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.vaccine.2014.11.048","article-title":"Recommendations regarding the development of combined enterotoxigenic Eschericha coli and Shigella vaccines for infants","volume":"33","author":"Walker","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2023.08.051_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay049","article-title":"Is a Shigella vaccine needed for travellers and the military?","volume":"25","author":"Riddle","year":"2018","journal-title":"Journal of Travel Medicine"},{"key":"10.1016\/j.vaccine.2023.08.051_b0090","article-title":"Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries","volume":"2","author":"Anderson JDt, Bagamian KH, Muhib F, Baral R, Laytner LA, Amaya M,","year":"2019","journal-title":"Vaccine X"},{"issue":"50","key":"10.1016\/j.vaccine.2023.08.051_b0095","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.1016\/j.vaccine.2017.09.083","article-title":"Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy","volume":"37","author":"Hosangadi","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.08.051_b0100","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1128\/IAI.06174-11","article-title":"Broadly protective Shigella vaccine based on type III secretion apparatus proteins","volume":"80","author":"Martinez-Becerra","year":"2012","journal-title":"Infection and Immunity"},{"key":"10.1016\/j.vaccine.2023.08.051_b0105","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the Global Enteric Multicenter Study (GEMS) Inform Vaccine Development","author":"Livio","year":"2014","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1016\/j.vaccine.2023.08.051_b0110","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/CVI.00435-08","article-title":"Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines","volume":"16","author":"Kaminski","year":"2009","journal-title":"Clinical and Vaccine Immunology"},{"issue":"9","key":"10.1016\/j.vaccine.2023.08.051_b0115","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.micinf.2008.07.016","article-title":"Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?","volume":"10","author":"Phalipon","year":"2008","journal-title":"Microbes and Infection"},{"issue":"4","key":"10.1016\/j.vaccine.2023.08.051_b0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrgastro.2013.12","article-title":"Progress and pitfalls in Shigella vaccine research","volume":"10","author":"Barry","year":"2013","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"28","key":"10.1016\/j.vaccine.2023.08.051_b0125","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.vaccine.2013.04.045","article-title":"Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD","volume":"31","author":"Heine","year":"2013","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.08.051_b0130","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrmicro1662","article-title":"Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007","journal-title":"Nature Reviews. Microbiology"},{"issue":"7","key":"10.1016\/j.vaccine.2023.08.051_b0135","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1128\/IAI.69.7.4545-4553.2001","article-title":"Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults","volume":"69","author":"Fries","year":"2001","journal-title":"Infection and Immunity"},{"issue":"40","key":"10.1016\/j.vaccine.2023.08.051_b0140","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2011.07.033","article-title":"Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine","volume":"29","author":"Riddle","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2023.08.051_b0145","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1128\/IAI.68.12.6624-6632.2000","article-title":"Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine","volume":"68","author":"Turbyfill","year":"2000","journal-title":"Infection and Immunity"},{"issue":"37","key":"10.1016\/j.vaccine.2023.08.051_b0150","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1016\/j.vaccine.2010.06.086","article-title":"Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers","volume":"28","author":"Tribble","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2023.08.051_b0155","article-title":"From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine's Refinement and Evolution","volume":"10","author":"Turbyfill","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.051_b0160","doi-asserted-by":"crossref","unstructured":"Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex. mSphere. 2018;3(2) https:\/\/doi.org\/10.1128\/msphere.00583-17.","DOI":"10.1128\/mSphere.00583-17"},{"issue":"4","key":"10.1016\/j.vaccine.2023.08.051_b0165","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00073-23","article-title":"Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei Artificial Invaplex (InvaplexAR) vaccines","volume":"8","author":"Turbyfill","year":"2023","journal-title":"mSphere"},{"issue":"11","key":"10.1016\/j.vaccine.2023.08.051_b0170","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1128\/iai.59.11.4075-4083.1991","article-title":"Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains","volume":"59","author":"Hartman","year":"1991","journal-title":"Infection and Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2023.08.051_b0175","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.idc.2006.09.004","article-title":"Reactive arthritis: defined etiologies, emerging pathophysiology, and unresolved treatment","volume":"20","author":"Carter","year":"2006","journal-title":"Infectious Disease Clinics of North America"},{"issue":"1","key":"10.1016\/j.vaccine.2023.08.051_b0180","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0889-857X(21)00707-9","article-title":"Do bacterial antigens cause reactive arthritis?","volume":"18","author":"Granfors","year":"1992","journal-title":"Rheumatic Diseases Clinics of North America"},{"issue":"3","key":"10.1016\/j.vaccine.2023.08.051_b0185","first-page":"500","article-title":"Bacterial lipopolysaccharide in synovial fluid cells in Shigella triggered reactive arthritis","volume":"19","author":"Granfors","year":"1992","journal-title":"The Journal of Rheumatology"},{"issue":"12","key":"10.1016\/j.vaccine.2023.08.051_b0190","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clinical and Vaccine Immunology"},{"issue":"5","key":"10.1016\/j.vaccine.2023.08.051_b0195","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00988-19","article-title":"Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G","volume":"5","author":"Clarkson","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2023.08.051_b0200","article-title":"A High-throughput Shigella-specific Bactericidal Assay","volume":"144","author":"Weerts","year":"2019","journal-title":"Journal of Visualized Experiments"},{"issue":"8","key":"10.1016\/j.vaccine.2023.08.051_b0205","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cyto.a.20864","article-title":"Low-cost, high-throughput, automated counting of bacterial colonies","volume":"77","author":"Clarke","year":"2010","journal-title":"Cytometry. Part A"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2023.08.051_b0210","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-1656(99)00185-6","article-title":"Endotoxin removal from protein solutions","volume":"76","author":"Petsch","year":"2000","journal-title":"Journal of Biotechnology"},{"issue":"10","key":"10.1016\/j.vaccine.2023.08.051_b0215","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.vaccine.2007.12.040","article-title":"Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a","volume":"26","author":"Turbyfill","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.08.051_b0220","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.cmi.2022.10.011","article-title":"Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data","volume":"29","author":"Cohen","year":"2023","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1016\/j.vaccine.2023.08.051_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103310","article-title":"Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection","volume":"66","author":"Talaat","year":"2021","journal-title":"eBioMedicine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.08.051_b0230","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/IAI.67.7.3437-3443.1999","article-title":"Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602","volume":"67","author":"Coster","year":"1999","journal-title":"Infection and Immunity"},{"issue":"3","key":"10.1016\/j.vaccine.2023.08.051_b0235","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/CVI.00683-13","article-title":"Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine","volume":"21","author":"Kaminski","year":"2014","journal-title":"Clinical and Vaccine Immunology"},{"issue":"8","key":"10.1016\/j.vaccine.2023.08.051_b0240","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1128\/IAI.71.8.4808-4814.2003","article-title":"Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers","volume":"71","author":"Qadri","year":"2003","journal-title":"Infection and Immunity"},{"issue":"2","key":"10.1016\/j.vaccine.2023.08.051_b0245","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00412-16","article-title":"Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study","volume":"24","author":"Shimanovich","year":"2017","journal-title":"Clinical and Vaccine Immunology"},{"key":"10.1016\/j.vaccine.2023.08.051_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbi.2017.08.005","article-title":"Identification of immune correlates of protection in Shigella infection by application of machine learning","volume":"74","author":"Arevalillo","year":"2017","journal-title":"Journal of Biomedical Informatics"},{"issue":"Suppl 8","key":"10.1016\/j.vaccine.2023.08.051_b0255","doi-asserted-by":"crossref","first-page":"S580","DOI":"10.1093\/cid\/ciz892","article-title":"Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies","volume":"69","author":"Talaat","year":"2019","journal-title":"Clinical Infectious Diseases"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:33:07Z","timestamp":1759404787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23009957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":51,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0264410X23009957"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GMP manufacture of Shigella flexneri 2a Artificial Invaplex (InvaplexAR) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}